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Abstract
The relative efﬁcacy, safety and ecological implications of macrolides vs. quinolones in the treatment of community-acquired pneumonia
(CAP) are debatable. We performed a systematic review and meta-analysis of randomized controlled trials comparing any macrolide vs.
any quinolone for the treatment of CAP among adult inpatients or outpatients, as monotherapy or both in combination with a beta-
lactam. We did not limit inclusion by pneumonia severity, publication status, language or date of publication. The primary outcomes
assessed were 30-day all-cause mortality and treatment failure. Two authors independently extracted the data. Fixed effect meta-analysis
of risk ratios (RRs) with 95% conﬁdence intervals was performed. Sixteen trials (4989 patients) fulﬁlling inclusion criteria were identi-
ﬁed, mostly assessing outpatients with mild to moderate CAP. All-cause mortality was not signiﬁcantly different for macrolides vs. qui-
nolones, RR 1.03 (0.63–1.68, seven trials), with a low event rate (2%). Treatment failure was signiﬁcantly lower with quinolones, RR
0.78 (0.67–0.91, 16 trials). The deﬁnition of failure used in the primary studies was not clearly representative of patients’ beneﬁt. Micro-
biological failure was lower with quinolones, RR 0.63 (0.49–0.81, 13 trials). All adverse events, adverse events requiring discontinuation
and any premature antibiotic discontinuation were signiﬁcantly more frequent with macrolides, mainly on account of gastrointestinal
adverse events. Resistance development was not assessed in the trials. Randomized controlled trials show an advantage of quinolones in
the treatment of CAP with regard to clinical cure without need for antibiotic modiﬁcation at end of treatment and gastrointestinal
adverse events. The clinical signiﬁcance of this advantage is unclear.
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Background
Community-acquired pneumonia (CAP) is a leading cause of
infectious morbidity and mortality. The overall incidence of
CAP is estimated worldwide to be between 5 and 11 per
1000 adult population, with more than ten-fold higher inci-
dence among the elderly [1]. The incidence of CAP requiring
hospital admission varies between 1.1 and 2.7 per 1000 in
the young adult population and 13.21 per 1000 persons
>55 years. [1] Current guidelines recommend macrolides as
ﬁrst-line treatment for CAP among outpatients [2–4]. A pen-
icillin precedes macrolides in the UK [1]. For outpatients
with co-morbidities and inpatients with non-severe CAP,
respiratory ﬂuoroquinolones alone or a beta-lactam com-
bined with a macrolide are recommended [3]. For severe
CAP managed in hospital, a combination treatment of beta-
lactams with macrolides or respiratory ﬂuoroquinolones is
recommended.
Observational studies report conﬂicting results regarding
the class effects of quinolones vs. macrolides in the treat-
ment of CAP. A prospective study conducted in an intensive
care unit (ICU) reported that macrolides were superior to
quinolones (both in combination with a beta-lactam) in 100
patients with severe CAP receiving guideline-adherent treat-
ment [5]. ICU mortality was 26% (12/46) with macrolides vs.
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46% (25/54) with quinolones (adjusted hazard ratio 0.48,
95% CI 0.23–0.97). In a retrospective study of patients with
Legionella pneumophila CAP, time to clinical stability and
length of hospital stay were in favour of levoﬂoxacin, without
achieving statistical signiﬁcance [6]. Among outpatients with
CAP, a retrospective study showed that levoﬂoxacin recipi-
ents were signiﬁcantly less likely to experience treatment
failure than macrolide recipients (adjusted odds ratio 0.84,
95% CI 0.75–0.94) [7]. Selection bias in observational studies
limits the validity of these results.
We conducted a systematic review and meta-analysis of
randomized controlled trials comparing (ﬂuoro)quinolones
vs. macrolides for CAP among inpatients and outpatients.
Methods
We included randomized controlled trials (RCTs) comparing
any quinolone vs. any macrolide, administered as monothera-
pies or both in combination with a beta-lactam antibiotic for
the treatment of CAP in adult inpatients or outpatients. We
permitted the use of different beta-lactams in the compara-
tor arms, assuming that the differences between the various
beta-lactams against Streptococcus pneumoniae (the main path-
ogen targeted by the beta-lactam in CAP) are minor. CAP
was deﬁned as a new radiographic inﬁltrate and at least one
positive ﬁnding out of the following: new onset of a cough,
purulent tracheobronchial secretions, fever or focal respira-
tory abnormalities on physical examination [3].
We deﬁned 30-day all-cause mortality and clinical failure
as primary outcomes. Clinical failure was deﬁned as persis-
tence of fever or other symptoms or signs of infection
beyond the protocol-deﬁned period for clinical response
(preferably days 3–4), need for antibiotic modiﬁcation during
the planned antibiotic course or 30-day mortality. If 30-day
mortality was unavailable we extracted deaths at end of fol-
low-up. Secondary outcomes included: development of com-
plications that were not present initially, including empyema,
respiratory failure and severe sepsis; superinfections; time to
defervescence; premature discontinuation of study drug for
any reason; need for hospitalization in community-treated
CAP; length of hospital stay; microbiological failure; and
adverse events. Microbiological failure was extracted as
deﬁned in the individual studies.
We searched PubMed, the Cochrane Central Register of
Controlled Trials (Central) and LILACS databases. The
search terms ‘pneumonia’ and individual quinolones and mac-
rolide drugs (Table S1) were combined with the Cochrane
ﬁlter for RCTs (except in Central) [8]. Unpublished trials
were sought in references of all selected studies, relevant
conference proceedings, trial registries and ongoing trial da-
tabases, new drug application documents of the FDA and
European Medicines Agency databases, and through personal
contact with the investigators and sponsoring pharmaceutical
companies of the included studies. No language or date
restrictions were imposed. The last search was conducted in
July 2011.
Two reviewers independently applied inclusion criteria
and extracted the data. Outcomes were extracted preferen-
tially by intention to treat. Missing data were requested from
the authors. Risk of bias was assessed using a domain-based
method as recommended in the Cochrane handbook [9].
Allocation concealment and generation were graded as low,
high or unknown risk of bias. Risk ratios (RRs) with 95%
conﬁdence intervals (CIs) were calculated for individual stud-
ies. Heterogeneity in the results of the trials was assessed
using the chi-square test for heterogeneity and I2 measure of
inconsistency [10]. Meta-analysis was conducted using the
Mantel–Haenszel ﬁxed-effects model. We planned subgroup
analyses by inpatient vs. outpatient management, type of
macrolide and by pathogen. We assessed the effects of risk
of bias and sponsorship and excluded quinolones withdrawn
from use in sensitivity analyses. Analyses were conducted
using Review Manager 5.1 [11].
Results
Eighty-three publications were retrieved for full text inspec-
tion, of which 67 were excluded, and 16 randomized con-
trolled trials published between 1993 and 2005 were
included in the review (Fig. 1). Eight trials included mostly
(‡70%) outpatients [12–19], four did not report the manage-
ment setting but were most probably conducted in the com-
munity [20–23] and four included mainly hospitalized patients
[24–27]. Most studies restricted inclusion to mild-moderate
CAP. The mean or median patients’ age ranged between 45
and 64 years. All trials assessed monotherapy with a quino-
lone vs. a macrolide, except for Gaillat et al. [25], who
assessed inpatients adding a beta-lactam to both arms. Anti-
biotics were given orally in all but two trials [24,25], in which
treatment was given intravenously initially. Treatment dura-
tion was deﬁned between 5 and 14 days (mean actual dura-
tion most commonly 10 days), except for one trial
administering a single dose of azithromycin [12]. Follow-up
ranged between 2 and 6 weeks. Study characteristics are
detailed in Table S2.
None of the trials reported on the methods of randomiza-
tion and allocation concealment (Table S3). All but two
[24,25] were double blinded. All trials deﬁned and reported
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clinical response as the primary outcome, but most did not
deﬁne secondary outcomes, thus the risk of selective out-
come reporting is unclear. Two trials were stopped prema-
turely [12,19].
All-cause mortality
All-cause mortality was reported in eight trials (2958
patients) with no signiﬁcant difference between study arms
(RR 1.03, 95% CI 0.63–1.68, without signiﬁcant heterogene-
ity, I2 = 0%) (Fig. 2). No difference in mortality rates
between study arms was demonstrated when analysing sepa-
rately trials including mostly outpatients (RR 0.96, 95% CI
0.53–1.72, four trials) and mostly inpatients (RR 1.23, 95% CI
0.49–3.06, three trials). Mortality rates in these trials were
2%. Due to the lack of heterogeneity and paucity of data
we did not proceed with further subgroup analyses.
Clinical failure
Clinical failure was deﬁned in included studies as persistence
of signs and symptoms of pneumonia requiring treatment
modiﬁcation or radiographic persistence or progression
between the end of treatment and 4 weeks later (see study
deﬁnitions in Table S3). Only pneumonia-related deaths were
included in the outcome deﬁnition. Clinical failure, as deﬁned
in the studies, was signiﬁcantly less frequent with quinolones
compared with macrolides overall (RR 0.78, 95% CI 0.67–
0.91, 16 trials, 4999 patients, without heterogeneity, I2 = 0%)
(Fig. 3). Results were similar at the end of treatment (RR
0.77, 95% CI 0.64–0.93, nine trials) and end of follow-up (RR
0.83, 95% CI 0.73–0.95,; 13 trials, without heterogeneity).
Results were similar with long-acting and short-acting mac-
rolides (Fig. 3). There were no signiﬁcant differences in effects
between mostly community-treated CAP (RR 0.78, 95% CI
0.65–0.94, 12 trials) and mostly hospitalized CAP (RR 0.76,
95% CI 0.58–1.00, four trials). The RRs were similar in smaller
subgroups of patients with documented pneumococcal CAP
(RR 0.84, 95% CI 0.51–1.37, eight trials, 361 patients), CAP
caused by Mycoplasma pneumoniae, Chlamydia pneumoniae or
Legionella sp. (RR 0.84, 95% CI 0.46–1.54, eight trials, 653
patients) and CAP with no identiﬁed aetiology (RR 0.83, 95%
16  included trials: 
Clarithromycin vs. gatifloxacin  
Clarithromycin vs levofloxacin  
Clarithromycin vs trovafloxacin  
Clarithromycin vs grepafloxacin  
Clarithromycin vs sparfloxacin  
Clarithromycin vs moxifloxacin  
Clarithromycin vs. garenoxacin  
Erythromycin vs sparfloxacin 
Erythromycin + amoxi-clavulonate vs. 
ofloxacin + penicillin  
Erythromycin vs. ofloxacin 
Azithromycin vs levofloxacin 
Roxithromycin vs sparfloxacin 
2 secondary publications of included
RCTs identified by the search   
49 incompatible comparisons 
2 measuring in vitro efficacy 
1 improper randomization 
10 non-comparative or non-randomised 
studies 
2 reviews, correspondence or editorial 
1 retrospective study 
18 potentially appropriate RCTs to be
included   
70 RCTs evaluated for inclusion  
83 potentially relevant articles 
identified by the search strategy  
FIG. 1. Trial ﬂow.1 References in excluded studies are provided in the Supplementary Material [1].
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Study or subgroup
Gaillat 1994 EryOfloBL
Lode 1995 ErySpar
Ortquist 1996 RoxSpar
Moola 1999 ClaGrepa
Remirez 1999 ClaSpar
Hoeffken 2001 ClaMoxi
D`Ignazio 2005 AziLevo
Total (95% CI)
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Heterogeneity: Chi² = 2.39, df = 6 (p = 0.88); I² = 0%
Test for overall effect: Z = 0.11 (p = 0.91)
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1.03 [0.63, 1.68]
Year
Risk ratio Risk ratioMacrolideQuinolone
M-H, Fixed, 95% CI
0.002 0.1 1 10 500
Favours quinolone       Favours macrolide
FIG. 2. All cause mortality. Studies are labelled by name of ﬁrst author, year of publication and interventions,1 subgrouped by type of macrolide
and sorted by year of publication. 1Ery, erythromycin; Oﬂo, oﬂoxacin; BL, beta-lactam; Spar, sparﬂoxacin; Rox, roxithromycin; Cla, clarythromy-
cin; Grepa, grepaﬂoxacin; Moxi, moxiﬂoxacin; Azi, azithromycin; Levo, levoﬂoxacin.
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FIG. 3. Clinical failure. Studies are labelled by name of ﬁrst author, year of publication and interventions1, subgrouped by type of macrolide and
sorted by year of publication. 1Ery, erythromycin; Oﬂo, oﬂoxacin; BL, beta-lactam; Spar, sparﬂoxacin; Rox, roxithromycin; Cla, clarythromycin;
Grepa, grepaﬂoxacin; Moxi, moxiﬂoxacin; Azi, azithromycin; Levo, levoﬂoxacin; Gati, gatiﬂoxacin; Trova, trovaﬂoxacin; Garen, grenoxacin.
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CI 0.70–0.98, six trials, 1921 patients), but results were statis-
tically signiﬁcant only for the latter subgroup.
Restricting the analysis to double-blinded trials did not
affect results. We observed no signiﬁcant difference between
the pooled RRs when restricting the analysis to trials spon-
sored by the macrolide-producing (RR 0.80, 95% CI 0.55–
1.15, three trials) or the quinolone-producing company (RR
0.77, 95% CI 0.65–0.93, 10 trials). The RR was similar when
excluding quinolones no longer in use (grepaﬂoxacin, gare-
noxacin and gatiﬂoxacin; RR 0.78, 95% CI 0.66–0.94).
Secondary outcomes
None of the trials reported on time to defervescence or
complications of pneumonia. Microbiological failure was sig-
niﬁcantly lower with quinolones (RR 0.63, 95% CI 0.49–0.81,
13 trials, 1895 patients, without heterogeneity) (Fig. 4).
Premature discontinuation of the study drug for any reason
was reported in four trials (RR 0.73, 95% CI 0.58–0.92,
I2 = 0%). Four trials reported bacterial superinfections (RR
1.87, 95% CI 0.63–5.52), with no events in two of the trials.
Resistance development was reported in two trials: one
reported no resistance in either group [19] and the other
reported the development of one multiresistant Pseudomonas
sp. per arm [25].
Adverse events in total and discontinuation due to
adverse events were signiﬁcantly lower with quinolones (RR
0.92, 95% CI 0.85–0.99, 11 trials, and RR 0.73, 95% CI 0.54–
0.99, nine trials, respectively, with moderate heterogeneity,
I2 = 40% and 33%, respectively). Diarrhoea occurred signiﬁ-
cantly less frequently with quinolones (RR 0.75, 95% CI
0.59–0.94, 13 trials, with moderate heterogeneity, I2 = 45%).
Excluding trials using erythromycin from the analysis did not
Study or subgroup
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FIG. 4. Microbiological failure. Studies are labelled by name of ﬁrst author, year of publication and interventions,1subgrouped by type of macro-
lide and sorted by year of publication.1Ery, erythromycin; Oﬂo, oﬂoxacin; BL, beta-lactam; Spar, sparﬂoxacin; Rox, roxithromycin; Cla, clarythro-
mycin; Grepa, grepaﬂoxacin; Moxi, moxiﬂoxacin; Azi, azithromycin; Levo, levoﬂoxacin; Gati, gatiﬂoxacin; Trova, trovaﬂoxacin; Garen, grenoxacin.
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change the signiﬁcant advantage of quinolones (RR 0.73, 95%
CI 0.56–0.94, 10 trials). Only one trial reported on Clostrid-
ium difﬁcile-associated diarrhoea (CDAD), with no events
[12]. The analysis of nausea and/or vomiting was heteroge-
neous; excluding trials assessing erythromycin there was no
signiﬁcant difference between macrolides and quinolones (RR
1.15, 95% CI 0.87–1.50, 11 trials, without heterogeneity,
I2 = 0%). Taste disturbances were signiﬁcantly less frequent
with quinolones (RR 0.42 (0.31–0.58), seven trials). Tendinitis
and tendon rupture were not reported. QT prolongation
was reported in ﬁve trials. The overall incidence was low: 7/
1122 (0.62%) in the quinolone arm, all with sparﬂoxacin; and
2/890 (0.22%) in the macrolide arm, one with roxithromycin
and one with clarithromycin. No cases of fatal arrhythmia
were reported.
Discussion
Sixteen randomized controlled trials assessing quinolones vs.
macrolides for the treatment of CAP were included in this
systematic review. There was no signiﬁcant difference in
mortality, but event rates were low because most trials
recruited outpatients with mild to moderate CAP. Treat-
ment with quinolones was signiﬁcantly superior to macro-
lides with respect to clinical response (RR 0.78, 95% CI
0.67–0.91). The number needed to treat with a quinolone to
prevent one failure was 37 patients (95% CI 24–87) with a
control event rate of 13%. Results were similar in all sub-
group analyses. All adverse events, adverse events requiring
discontinuation of study drug, diarrhoea and taste distur-
bances were signiﬁcantly less frequent with the quinolone
regimen in all trials.
To adopt a policy using primarily macrolides or quinol-
ones in the treatment of CAP, we should consider their
comparative effectiveness, adverse effects and impact on
resistance development. The clinical and microbiological
advantage we found for quinolones might be biologically plau-
sible: lower resistance rates of S. pneumonia to quinolones
vs. macrolides [28,29] and respective bactericidal vs. bacte-
riostatic activity when administered alone. However, we
should ask whether the advantage we observed is clinically
meaningful. The studies did not report on duration of fever,
days off work, need for hospitalization and duration of hospi-
talization. Less than half of all trials reported on all-cause
mortality. CDAD, a relevant outcome with quinolone ther-
apy, was reported in a single study. The relevance of micro-
biological failure, assessed in a minority of patients in most
of the trials, is unclear. Failure to eradicate identiﬁed patho-
gens does not necessarily mean clinical failure. The primary
outcome in all studies was assessed at least 7 days after start
of treatment and usually much later. Early studies in the
beginning of the antibiotic era showed that most patients
with pneumonia are clinically cured by 72 h after start of
antibiotics [30,31]. This is probably the more appropriate
time-point to compare treatment effects and is also more
relevant to the patient treated. In a position paper on the
design of trials assessing antibiotics for community-acquired
pneumonia, the Infectious Diseases Society of America rec-
ommended the assessment of all-cause mortality as primary
outcome for severe CAP [32]. For mild or moderate pneu-
monia assessment of 15-day all-cause mortality was recom-
mended, ‘either as the lead outcome in a hierarchical
endpoint or as a composite endpoint with morbidity vari-
ables that represent meaningful beneﬁt to patients and are
assessed by Patient Reported Outcome (PRO) instruments’
[32]. The compiled data in our review show that there is
less need for antibiotic modiﬁcations and fewer gastrointesti-
nal adverse events with quinolones than with macrolides. It
is difﬁcult to base a treatment policy on these results.
Comparative ecological impact should consider the effect
of use on pathogens’ susceptibility to the antibiotic used,
cross-resistance with other antibiotics and the spectrum of
pathogens affected. Studies in healthy volunteers showed that
administration of macrolides results in development of mac-
rolide-resistant microﬂora in the individual treated within a
few days, which can be detected for about 1 month post-
treatment [33–37]. The effect of quinolone administration
was more variable, with several studies claiming no detection
of resistant bacteria, from a baseline of no resistance [37–
41]. However, the effects of macrolides are limited to strep-
tococci, while quinolones may affect enterobactericeae,
streptococci, staphylococci and sometimes anaerobes. In the
hospital, quinolone consumption has been correlated with
quinolone and cephalosporin-resistant enterobactericeae,
quinolone-resistant P. aeruginosa, carbapenem-resistant Acinet-
obacter sp. and methicillin-resistant S. aureus (MRSA) [42–46].
Macrolide use has been associated with MRSA, but not with
resistance in Gram-negative bacteria [47]. In the community,
macrolides contribute to the appearance of macrolide and
penicillin-resistant S. pneumonia [48–51]. Widespread quino-
lone use may affect the epidemiology of respiratory patho-
gens and susceptibility of bacteria causing urinary tract
infections [52]. Both may contribute to the spread of com-
munity-acquired MRSA [53]. In RCTs the comparative eco-
logical effects of quinolones vs. macrolides were not
reported.
Several limitations of the systematic review and current
evidence should be noted. Although selection between mac-
rolides and quinolones is mainly relevant to inpatients with
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severe CAP, we found only four trials that included mainly
inpatients. Most studies were conducted more than a decade
ago. Several quinolones have been withdrawn from clinical
use since the conduct of the trials, including grepaﬂoxacin,
garenoxacin and gatiﬂoxacin (in adults). Trovaﬂoxacin’s use
has been restricted to severe CAP [54] and sparﬂoxacin is
not available in the USA. The trials presented primarily analy-
ses for modiﬁed-ITT and clinically-evaluable populations. ITT
results might bias results towards no difference in non-inferi-
ority studies [55]. However, we opted for ITT analysis
because in clinical practice we are interested in the results
for all patients treated (the ITT population) and derivation of
the per-protocol population in included trials could have led
to other bias.
In summary, the current review does not provide strong
support for selection of macrolides or quinolones for the
treatment of CAP. Quinolones resulted in higher treatment
success. The main limitation lies in the interpretation of this
outcome and the lack of data on the relative impact of these
antibiotic classes on resistance development. Future RCTs
should assess and report on outcomes more directly rele-
vant to the individual patient treated in the community and
in the hospital [32]. Observational studies should be
designed to compare the ecological effects of a policy using
quinolones vs. that using macrolides.
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